Results of R-ESHAP as salvage therapy in refractory/relapsed follicular lymphoma: a real-world experience on behalf of GELCAB group-Reference-Cited by-同舟云学术

Results of R-ESHAP as salvage therapy in refractory/relapsed follicular lymphoma: a real-world experience on behalf of GELCAB group

Published:2020-05-25 Issue:7 Volume:99 Page:1627-1634
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Muntañola A.,Baumann T.,Caballero A. C.,Sánchez-González B.,Mercadal S.,Escoda L.,Soler A.,Iserte L.,Canet M.,Villalobos M. T.,Magnano L.,Sorigué M.,García O.,Salar A.,López-Guillermo A.,Sancho J. M.

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-020-04101-7.pdf

Reference31 articles.

1. Swerdlow S, Campo E, Harris NL. et al. Follicular Lymphoma. WHO Classification of tumours of haematopoietic and lymphoid tissues. Revised 4th Edition, 266-273. 2017.

2. Tan D, Horning SJ, Hoppe RT. Levy R, Rosenberg SA, Sigal BM, Warnke RA, Natkunam Y, Han SS, Yuen A, Plevritis SK, Advani RH. (2013) Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Standford University experience. Blood. ;122(6):981-987. https://doi.org/10.1182/blood-2013-03-491514.

3. Magnano L, Alonso-Alvarez S, Alcoceba M, Rivas-Delgado A, Muntañola A, Nadeu F, Setoain X, Rodríguez S, Andrade-Campos M, Espinosa-Lara N, Rodríguez G, Sancho JM, Moreno M, Mercadal S, Carro I, Salar A, Garcia-Pallarols F, Arranz R, Cannata J, Terol MJ, Teruel AI, Jiménez-Ubieto A, Rodriguez A, González de Villambrosía S, Bello JL, López L, Novelli S, de Cabo E, Infante ME, Pardal E, Monsalvo S, González M, Martín A, Caballero MD, López-Guillermo A, Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea (GELTAMO) (2019) Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population. Br J Haematol 185(3):480–491. https://doi.org/10.1111/bjh.15805

4. Maurer MJ, Bachy E, Ghesquières H, Ansell SM, Nowakowski GS, Thompson CA, Inwards DJ, Allmer C, Chassagne-Clément C, Nicolas-Virelizier E, Sebban C, Lebras L, Sarkozy C, Macon WR, Feldman AL, Syrbu SI, Traverse-Glehan A, Coiffier B, Slager SL, Weiner GJ, Witzig TE, Habermann TM, Salles G, Cerhan JR, Link BK (2016) Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am JHematol 91(11):1096–1101. https://doi.org/10.1002/ajh.24492

5. Rivas-Delgado A, Magnano L, Moreno-Velázquez M, Garcia O, Nadeu F, Mozas P, Dlouhy I, Baumann T, Rovira J, González-Farré B, Martínez A, Balagué O, Delgado J, Villamor N, Giné E, Campo E, Sancho-Cía JM, López-Guillermo A (2019) Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era. Br J Haematol 184(5):753–759. https://doi.org/10.1111/bjh.15708

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost–effectiveness of obinutuzumab plus bendamustine in Chinese patients with relapse and refractory follicular lymphoma;Journal of Comparative Effectiveness Research;2023-12

2. Clinical outcomes in patients relapsed/refractory after ≥2 prior lines of therapy for follicular lymphoma: a systematic literature review and meta-analysis;BMC Cancer;2023-01-23

3. Hypercalcemia and bulky primary adrenal non-Hodgkin lymphoma: A case report;Medicina Clínica (English Edition);2021-12

4. Hypercalcemia and bulky primary adrenal non-Hodgkin lymphoma: A case report;Medicina Clínica;2021-12

5. Novel Therapy Approaches to Follicular Lymphoma;Drugs;2021-02-22